A competitive polymerase chain reaction (cPCR) assay for the quantitative evaluation of Mycobacteriurn tuberculosis growth was developed based on co-amplification of genomic DNA and a modified DNA fragment derived from a well-conserved region of the 16s rRNA gene. There was a good correlation between the number of DNA copies in the sample, indicated by competitive PCR, and the number of colony forming units determined by conventional culture methods.
Introduction
Quantitative evaluation of growth is an essential tool in diagnostic microbiology, in studies on the pathogenesis of bacterial diseases and in antimicrobial drug efficacy testing. Procedures based on culture techniques are the most sensitive and specific; unfortunately, they do not provide. rapid results when applied to quantification of slow-growing bacteria such as Mycobacterium tuberculosis.
Competitive polymerase chain reaction (cPCR)-based assays have been proposed in recent years for quantitative detection of micro-organisms. In such procedures a range of concentrations of a modified PCR product and target DNA bearing the same primer recognition sequences are co-amplified in the same tube. The resulting products must be clearly distinguishable by gel electrophoresis analysis, in order to allow densitometric comparison of the relative intensities of the bands for both DNA species. The point at which modified DNA and target DNA give the same amount of products is determined and defines the concentration in the test sample. cPCR has been applied to the direct detection and quantification of M. tuberculosis in clinical samples . These assays are based on the insertion element IS6110, which is specific for strains belonging to the M. tuberculosis complex.
In the present study a quantitative assay for myco- bacterial growth based on cPCR was developed. In this assay a modified DNA fragment derived from a well conserved region of the 16s rRNA gene, which is present as one copy per chromosome in slow growing mycobacteria [4-61, is co-amplified with wild-type DNA. This method was shown to give results comparable with those obtained with conventional culture-based determination of the number of colony forming units (cfu), and provided a result at least 2 weeks earlier than culture.
Materials and methods
Bacterial strain and DNA preparation M. tuberculosis clinical isolates (identified to species level by standard biochemical methods [7] ) were used in this study and were grown in Middlebrook 7H-9 medium (Difco) at 37°C in air for 10-14 days until a turbidity equal to that of no. 1 McFarland standard ( g 1 X lo8 cfu/ml) was reached. For DNA preparation, cells from 1 ml of culture were harvested and washed in 10 mM Tris, 1 mM EDTA (TE) buffer. The pellet was resuspended in 1 ml of 10 mM Tris, 10 mM EDTA, Tween 80 0.1% and heat-inactivated at 80°C for 30 min. Samples were pelleted again and the cells were resuspended in 85 pl of the same buffer containing lysozyme (Boehringer GmbH, Mannheim, Germany) 2 mg/ml. After incubation for 1 h at 37"C, 10 pl of SDS 1% and 5 pl of proteinase K 1 mg/ml were added to each sample and the suspension was incubated again for 1 h at 37°C. After centrifugation at 11 000 g for 10 min at 4"C, the supernate was transferred to another tube and used as a source of DNA in the amplification reaction. The final volume of extracted DNA was 100 pl.
Synthesis of competitor DNA volume. After amplification, 10 pl of.the mixture were electrophoresed on ethidium bromide (0.5 pg/ml)-containing agarose (FMC, BioProducts, Rockland, ME, USA) 3% gels or acrylamide 6% gels in TBE buffer (45 Samples (100 pl) of 10-2-10-5 dilutions of the cultures were placed into 7H-10 medium contained in a plastic quadrant of a four-quadrant plate. Plates were allowed to dry and placed in individual C02-permeable polyethylene bags at 37°C in C02 5-10%. After 2-4 weeks colonies were counted and the number of cfu was determined.
for 1 min, primer annealing at 60°C for 2 min and extension at 72°C for 6 min. The amplification products
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were quantified by measuring the A260 with an LKB Biochrom Ultrospec I1 spectrophotometer (Pharmacia Inc., Italy), assuming an A260 of 1 corresponds to a concentration of 50 pg of DNA/ml. This estimation was also confirmed by end-point dilution amplification. This was performed by diluting the amplification products in triplicate and amplifying 2 pl of each dilution. The dilution end-point was defined as the greatest dilution that gave detectable amplification products in a PCR assay. The Poisson distribution of positive samples showed that the sensitivity was 1 molecule.
cPCR
The cPCR assay was performed initially with DNA from the VR16 strain and its own derived competitor DNA. Subsequently, wild-type DNA from other strains (10 clinical isolates from our collection) was tested. DNA was extracted from triplicate samples (1 ml/sample) of a culture in Middlebrook 7H-9 medium which was adjusted to no. 1 McFarland turbidity. For each sample four parallel reactions were performed, each of which contained the MT1 and MT2 primer pair, 2 pl of wild-type DNA and decreasing copy numbers of competitor DNA molecules ( lo7 -1 04). Amplification was carried out as described above in a 100 pl final A 100-pl volume of a M. tuberculosis VR16 culture adjusted to no. 1 McFarland turbidity was diluted 1 in 1000 in Middlebrook 7H-9 medium containing isoniazid at 0.2 and 1 pglml. The number of DNA copies and cfu were determined in l-ml samples taken at 0, 2 and 4 days. The same competitor copy number range (104-108) was used in all the cPCR susceptibility assays.
Results and discussion
Comparison experiments were performed between the cPCR assay and cfw determination. Fig. 1 (inset) illustrates a representative determination of the DNA copy number of the bacterial suspension. It is clear that increasing the copy number of the competitor DNA (lower band) progressively competed with the wild-type DNA sequence (upper band). A regression curve was obtained by comparing the DAc/WA ratio with the copy number of the competitor DNA. The equivalence point was calculated according to the regression curve and the value of 1.4 X lo6 (corresponding to 7 X lo7 copies/ml of the starting cell suspension) was assigned to the wild-type copy number. The average copy number obtained from the three determinations was 6.5 (SD 0.5) X lo7. Three determinations of cfu/ml of At the equivalence point (y = l), a DNA copy number of 1.4 X lo6 was found by interpolation; this represented the number of wild-type DNA copies present in 20 yl of the original cell suspension.
the same bacterial suspension yielded a mean value of 7.9 (SD 0.3) X lo7. The same comparison experiments were made with 10 additional clinical isolates of M. tuberculosis from our collection. The cPCR results were plotted against cfu determination and a regression line calculated with y = 7.2 X lo6 + 0 . 9 9~ (data not shown). A value of r = 0.947 was obtained, indicating a good correlation between the two methods. In general, cPCR gave higher values than cfu determinations (from 3 to 25% higher).
As an example of the possible applications of the cPCR assay, evaluation of M. tuberculosis growth was performed in the presence or absence of isoniazid (INH, 0.2 and 1 pglml). As shown in Fig. 2 and Table 1 , after incubation for 2 days, the DNA copy number of both the INH-containing samples was nearly 1 loglo lower than that of the control at time 0 and > 2 loglo lower after incubation for 4 days. As compared with the control at time 0, the decrease in cfu was 90% (INH, 0.2pg/ml) and 92% (INH, 1 pg/ml) after 2 days; 95% (INH, 0.2 pg/ml) and 98% (INH, 1 pglml) after 4 days. The inhibitory effect of INH was detected visually in broth cultures after incubation for 8 days; colonies were detected after 16 days. cPCR was performed with 2 pl of DNA corresponding to 20 pl of the original cell suspension. The number of DNA copies contained in 1 ml of the original cell suspension was obtained by multiplying by 50 the number of copies calculated by the cPCR assay.
In conclusion, the cPCR assay described here is a suitable method for the rapid monitoring of M. tuberculosis growth and, for the development of rapid susceptibility assays, constitutes a promising approach warranting further investigation. An advantage over the IS6IIO-based cPCR [l-31 is that the 16s rRNAbased cPCR is likely to work with mycobacteria other than M. tuberculosis.
